Browsing by Author Mortier, Laurent

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 7 of 7
Issue DateTitleAuthor(s)Citation
2012Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialKefford, Richard (Rick); Long, Georgina; Algazi, Alain; Ascierto, Paolo; Chapman, Paul; Davies, Michael; et al, Various; Hauschild, A; Mortier, Laurent; Puzanov, Igor; Robert, C; Tawbi, Hussein; Trefzer, Uwe; Western Clinical School: Westmead Millennium Institute; Central Clinical School: The Sydney Cancer CentreDabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial, The Lancet Oncology, vol.13, 11, 2012,pp 1087-1095
2017Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trialLong, Georgina; Arance, Ana; Chiarion-Sileni, Vanna; Davies, Michael; Del Vecchio, M; Flaherty, Keith; Grob, Jean-Jacques; Hogg, David; Huang, Yingjie; Lebbe, Celeste; Lesimple, Thierry; Márquez-Rodas, Ivan; Meyer, Nicolas; Mookerjee, Bijoyesh P; Mortier, Laurent; Moschos, S; Robert, Caroline; Saiag, Philippe; Thomas, Luc; Zhang, Ying; Northern Clinical School: MedicineDabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial, The Lancet Oncology, vol.18, 7, 2017,pp 863-873
2013Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced MelanomaKefford, Richard (Rick); Chiarion-Sileni, Vanna; Eggermon, Alexander; et al, Various; Grob, Jean Jacques; Mackiewicz, Jacek; Mortier, Laurent; O'Day, Steven; Robert, Caroline; Schachter, Jacob; Testori, Alessandro; Western Clinical School: Westmead Millennium InstituteFinal Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma, Journal of Clinical Oncology, vol.31, 9, 2013,pp 1211-1218
2015Improved overall survival in melanoma with combined dabrafenib and trametinibLong, Georgina; Chiarion-Sileni, Vanna; Dummer, R; et al, Various; Grange, Florent; Karaszewska, Boguslawa; Lichinitser, Michael; Mackiewicz, Andrzej; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Schachter, Jacob; Stroiakovski, Daniel; Central Clinical School: The Sydney Cancer CentreImproved overall survival in melanoma with combined dabrafenib and trametinib, New England Journal of Medicine, vol.372, 1, 2015,pp 30-39
2015Nivolumab in Previously Untreated Melanoma without BRAF MutationLong, Georgina; Brady, Ben; Dutriaux, Caroline; et al, Various; Hassel, Jessica; Hernberg, Micaela; Kalinka-Warzocha, Ewa; Maio, Michele; McNeil, Catriona; Mortier, Laurent; Robert, Caroline; Rutkowski, Piotr; Savage, Kerry; Central Clinical School: The Sydney Cancer CentreNivolumab in Previously Untreated Melanoma without BRAF Mutation, The New England Journal of Medicine, vol.372, 4, 2015,pp 320-330
2017Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)Carlino, Matteo; Long, Georgina; Arance, A; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lotem, Michal; McNeil, Catriona M.; Mortier, Laurent; Ribas, Antoni; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Northern Clinical School: MedicinePembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006), The Lancet, vol.390, 10105, 2017,pp 1853-1862
2015Pembrolizumab versus ipilimumab in advanced melanomaCarlino, Matteo; Long, Georgina; Arance, Ana; Daud, Adil; et al, Various; Grob, Jean Jacques; Larkin, James; Lorigan, Paul; Lotem, Michal; McNeil, Catriona; Mortier, Laurent; Neyns, Bart; Robert, Caroline; Schachter, Jacob; Western Clinical School: Medicine (Westmead); Central Clinical School: The Sydney Cancer CentrePembrolizumab versus ipilimumab in advanced melanoma, The New England Journal of Medicine, vol.372, 26, 2015,pp 2521-2532